Entries by Joachim Eeckhout

Remynd receives €3.5M for Alzheimer’s trial

Belgian biotech Remynd has secured a €3.5 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to move its septin-modulating drug REM392 into patients with mild-to-moderate Alzheimer’s disease.

Novartis licenses BoomRay radioligand asset for $900M

Novartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma group’s core oncology platforms.

Novartis pays $125M for Sironax brain delivery platform

Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will retain rights to use the technology for selected assets.

Orbis lands $1.4B macrocycle partnership with Novo

Novo has entered a collaboration and licensing agreement with Danish biotech Orbis Medicines worth up to $1.4 billion (€1.2 billion) to discover oral macrocycle drugs for cardiometabolic diseases. Novo will also make an undisclosed strategic investment in Orbis.

Roche taps Dualitas in $1B bispecific deal

Roche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases.

,

The Strüngmann legacy, passed on

Thomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family office, an award bearing their name is turning that investment philosophy into a search for Europe’s next biotech builders.

Axoltis ALS drug misses Phase 2 endpoint

French biotech Axoltis Pharma’s NX210c missed the primary endpoint of a Phase 2 trial in amyotrophic lateral sclerosis (ALS), but post-hoc analyses showing slower functional decline are giving the company enough encouragement to plan further development.